(-0.06%) 5 144.00 points
(-0.06%) 38 535 points
(-0.11%) 17 884 points
(0.51%) $83.05
(2.86%) $2.09
(-1.43%) $2 324.10
(-2.68%) $26.92
(-1.29%) $949.10
(0.02%) $0.933
(0.39%) $11.03
(0.15%) $0.797
(-0.02%) $93.28
Live Chart Being Loaded With Signals
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally...
Stats | |
---|---|
आज की मात्रा | 7.05M |
औसत मात्रा | 501 174 |
बाजार मूल्य | 13.52B |
EPS | HKD0.0135 ( 2023-09-30 ) |
Last Dividend | HKD0.112 ( 2023-05-24 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -5.79 |
ATR14 | HKD0.00800 (0.24%) |
मात्रा सहसंबंध
Shenzhen Hepalink सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध |
---|
10 सबसे अधिक नकारात्मक सहसंबंध |
---|
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Shenzhen Hepalink सहसंबंध - मुद्रा/वस्त्र
Shenzhen Hepalink वित्तीय
Annual | 2023 |
राजस्व: | HKD5.45B |
सकल लाभ: | HKD1.80B (33.06 %) |
EPS: | HKD-0.530 |
FY | 2023 |
राजस्व: | HKD5.45B |
सकल लाभ: | HKD1.80B (33.06 %) |
EPS: | HKD-0.530 |
FY | 2022 |
राजस्व: | HKD7.16B |
सकल लाभ: | HKD2.33B (32.61 %) |
EPS: | HKD0.500 |
FY | 2021 |
राजस्व: | HKD6.37B |
सकल लाभ: | HKD2.03B (31.94 %) |
EPS: | HKD0.180 |
Financial Reports:
No articles found.
Shenzhen Hepalink Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.112 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.180 | 2021-05-28 |
Last Dividend | HKD0.112 | 2023-05-24 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | HKD0.333 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.36 | -- |
Div. Sustainability Score | 3.30 | |
Div.Growth Potential Score | 2.21 | |
Div. Directional Score | 2.75 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2359.HK | Ex Dividend Knight | 2023-06-05 | Annually | 0 | 0.00% | |
1345.HK | Ex Dividend Junior | 2023-10-04 | Semi-Annually | 0 | 0.00% | |
0390.HK | Ex Dividend Knight | 2023-07-19 | Annually | 0 | 0.00% | |
6626.HK | Ex Dividend Knight | 2023-09-04 | Annually | 0 | 0.00% | |
1897.HK | Ex Dividend Knight | 2023-07-05 | Semi-Annually | 0 | 0.00% | |
0921.HK | Ex Dividend Junior | 2023-07-10 | Sporadic | 0 | 0.00% | |
0052.HK | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
2869.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% | |
1469.HK | Ex Dividend Knight | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
0546.HK | Ex Dividend Knight | 2023-09-18 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.144 | 1.500 | -2.88 | -4.32 | [0 - 0.5] |
returnOnAssetsTTM | -0.0408 | 1.200 | -1.360 | -1.631 | [0 - 0.3] |
returnOnEquityTTM | -0.0638 | 1.500 | -1.820 | -2.73 | [0.1 - 1] |
payoutRatioTTM | -0.544 | -1.000 | -5.44 | 5.44 | [0 - 1] |
currentRatioTTM | 2.13 | 0.800 | 4.37 | 3.49 | [1 - 3] |
quickRatioTTM | 0.756 | 0.800 | -0.256 | -0.205 | [0.8 - 2.5] |
cashRatioTTM | 0.371 | 1.500 | 9.05 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.290 | -1.500 | 5.17 | -7.76 | [0 - 0.6] |
interestCoverageTTM | -3.86 | 1.000 | -2.54 | -2.54 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.462 | 2.00 | 9.85 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.159 | 2.00 | 9.92 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.467 | -1.500 | 8.13 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.331 | 1.000 | 7.82 | 7.82 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.158 | 1.000 | -5.16 | -5.16 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.122 | 1.000 | -0.433 | -0.433 | [0.2 - 2] |
assetTurnoverTTM | 0.284 | 0.800 | -1.443 | -1.154 | [0.5 - 2] |
Total Score | 3.30 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -6.02 | 1.000 | -0.709 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0638 | 2.50 | -1.170 | -2.73 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.159 | 2.00 | 9.95 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.49 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.462 | 2.00 | 9.85 | 10.00 | [0 - 30] |
payoutRatioTTM | -0.544 | 1.500 | -5.44 | 5.44 | [0 - 1] |
pegRatioTTM | -0.0488 | 1.500 | -3.66 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.125 | 1.000 | 9.38 | 0 | [0.1 - 0.5] |
Total Score | 2.21 |
Shenzhen Hepalink
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं